nephrology-chronic-diseases-2019-posters-abstracts

9 / 18

Page 37
Volume 2 Journal of Clinical Diagnosis and Treatment Annual Nephrology & Chronic Diseases 2019
May 20-21, 2019
Nephrology
Chronic Diseases May 20-21, 2019 London, UK
19th Annual Conference on
3rd International Conference on
&
Treatment outcomes of direct-acting antiviral (DAA) therapy among chronic kidney
disease (CKD) and post kidney transplant patients with hepatitis c virus (HCV)
infection: Single center experience
Shena Jo A Capucion and Jamias Jade D
National Kidney and Transplant Institute, Philippines
Background: Hepatitis C virus (HCV) infection is common among chronic kidney disease (CKD) and kidney
transplant recipients. Direct acting antiviral (DAA) regimens has been demonstrated to be effective with high
sustained virological response (SVR) rates and tolerated in the general population. Data is limited and remains
to be confirmed among CKD and kidney transplant recipients.
Objectives: The study aims to investigate treatment outcomes of DAA therapy among CKD and kidney
transplant patients with hepatitis C infection. Specifically, it seeks to describe demographics, determine SVR
rates, changes in laboratory values, and adverse effects with DAA therapy.
Methods: The study employed a retrospective observational study design. It included all cases of CKD and
kidney transplant recipients with chronic HCV infection who are >18-year-old on DAA Therapy at National
Kidney and Transplant Institute, Philippines from December 2015 to December 2016. Descriptive analysis of
treatment outcomes, changes in laboratory values, and adverse events.
Results: Twelve patients were included, 7 (58%) CKD and 5 (42%) kidney transplant recipients. All patients
(100%) had SVR 12. Changes in laboratory values during treatment included; (1) mean increase in creatinine
of 0.3 mg/dL vs 0.04 mg/dL, (2) mean decline in hemoglobin of 2 mg/dL vs 1.5 mg/dL, in platelet of 18 x 10^3/
uL vs. 7 x 10^3/uL, in ALT levels of 31 U/L vs 27 U/L, and in bilirubin 0.5 mg/dL vs 0.12 mg/dL in CKD and
post kidney transplant recipients respectively. One (8.3%) kidney transplant recipient had disorientation but
did not lead to treatment discontinuation.
Conclusions/Recommendations: Our study showed an SVR12 rate of 100% in both CKD and kidney
transplant recipients. Majority did not experience adverse effects during treatment. Further larger studies are
needed to validate our findings.
J Clinical Diagnosis and Treatment, Volume 2